Culine, S.; Harter, V.; Krucker, C.; Gravis, G.; Fléchon, A.; Chevreau, C.; Mahammedi, H.; Laguerre, B.; Guillot, A.; Joly, F.;
et al. Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Cancers 2023, 15, 1742.
https://doi.org/10.3390/cancers15061742
AMA Style
Culine S, Harter V, Krucker C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F,
et al. Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Cancers. 2023; 15(6):1742.
https://doi.org/10.3390/cancers15061742
Chicago/Turabian Style
Culine, Stéphane, Valentin Harter, Clémentine Krucker, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly,
and et al. 2023. "Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial" Cancers 15, no. 6: 1742.
https://doi.org/10.3390/cancers15061742
APA Style
Culine, S., Harter, V., Krucker, C., Gravis, G., Fléchon, A., Chevreau, C., Mahammedi, H., Laguerre, B., Guillot, A., Joly, F., Fontugne, J., Allory, Y., & Pfister, C., on behalf of the VESPER Trial Investigators.
(2023). Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Cancers, 15(6), 1742.
https://doi.org/10.3390/cancers15061742
